Physician profile
Elena Somma
NPI 1659417996
$1,766.83
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $842 · 2020: $478 · 2021: $360 · 2022: $86.90.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $377.80 | 2019-2022 | |
| Astellas Pharma US INC | $183.31 | 2019-2021 | |
| Glaxosmithkline, LLC. | $141.19 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $128.48 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.34 | 2019-2020 | |
| Abbvie INC. | $112.49 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $89.50 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $75.09 | 2019-2021 | |
| Pfizer INC. | $71.58 | 2019-2020 | |
| Lilly USA, LLC | $70.97 | 2019-2021 | |
| Amgen INC. | $51.17 | 2019-2020 | |
| Amarin Pharma, INC. | $41.14 | 2019 | |
| Sanofi Pasteur INC. | $38.43 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $33.25 | 2021 | |
| Abbott Laboratories | $26.75 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $22.79 | 2019 | |
| Scilex Pharmaceuticals INC. | $19.17 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.47 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $18.18 | 2019 | |
| Allergan, INC. | $17.48 | 2019 | |
| Corcept Therapeutics | $17.33 | 2019 | |
| Genentech USA, INC. | $17.00 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.27 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.07 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.96 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.39 | 2019 | |
| Bausch Health US, LLC | $12.31 | 2021 | |
| Seqirus USA INC | $10.92 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elena Somma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.